TRDA Relative Valuation
TRDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRDA is overvalued; if below, it's undervalued.
Historical Valuation
Entrada Therapeutics Inc (TRDA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.93. The fair price of Entrada Therapeutics Inc (TRDA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：10.26
Fair
-2.50
PE
1Y
3Y
5Y
Trailing
Forward
-0.44
EV/EBITDA
Entrada Therapeutics Inc. (TRDA) has a current EV/EBITDA of -0.44. The 5-year average EV/EBITDA is -1.46. The thresholds are as follows: Strongly Undervalued below -12.50, Undervalued between -12.50 and -6.98, Fairly Valued between 4.06 and -6.98, Overvalued between 4.06 and 9.59, and Strongly Overvalued above 9.59. The current Forward EV/EBITDA of -0.44 falls within the Historic Trend Line -Fairly Valued range.
-0.43
EV/EBIT
Entrada Therapeutics Inc. (TRDA) has a current EV/EBIT of -0.43. The 5-year average EV/EBIT is -1.31. The thresholds are as follows: Strongly Undervalued below -14.85, Undervalued between -14.85 and -8.08, Fairly Valued between 5.47 and -8.08, Overvalued between 5.47 and 12.24, and Strongly Overvalued above 12.24. The current Forward EV/EBIT of -0.43 falls within the Historic Trend Line -Fairly Valued range.
22.88
PS
Entrada Therapeutics Inc. (TRDA) has a current PS of 22.88. The 5-year average PS is 6.91. The thresholds are as follows: Strongly Undervalued below -4.82, Undervalued between -4.82 and 1.05, Fairly Valued between 12.78 and 1.05, Overvalued between 12.78 and 18.65, and Strongly Overvalued above 18.65. The current Forward PS of 22.88 falls within the Strongly Overvalued range.
0.00
P/OCF
Entrada Therapeutics Inc. (TRDA) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.61. The thresholds are as follows: Strongly Undervalued below -15.73, Undervalued between -15.73 and -8.67, Fairly Valued between 5.44 and -8.67, Overvalued between 5.44 and 12.50, and Strongly Overvalued above 12.50. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Entrada Therapeutics Inc. (TRDA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Entrada Therapeutics Inc (TRDA) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.53 , the current P/B ratio is approximately -30.92% higher. Relative to its 5-year average P/B ratio of 1.42, the current P/B ratio is about -25.33% higher. Entrada Therapeutics Inc (TRDA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.27%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -9.71% , the current FCF yield is about -100.00% lower.
1.07
P/B
Median3y
1.53
Median5y
1.42
-35.94
FCF Yield
Median3y
-6.27
Median5y
-9.71
Competitors Valuation Multiple
The average P/S ratio for TRDA's competitors is 0.00, providing a benchmark for relative valuation. Entrada Therapeutics Inc Corp (TRDA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -91.75%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TRDA decreased by 41.24% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -71.70 to -2.73K.
The secondary factor is the Revenue Growth, contributed -91.75%to the performance.
Overall, the performance of TRDA in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Entrada Therapeutics Inc (TRDA) currently overvalued or undervalued?
What is Entrada Therapeutics Inc (TRDA) fair value?
How does TRDA's valuation metrics compare to the industry average?
What is the current P/B ratio for Entrada Therapeutics Inc (TRDA) as of Dec 05 2025?
What is the current FCF Yield for Entrada Therapeutics Inc (TRDA) as of Dec 05 2025?
What is the current Forward P/E ratio for Entrada Therapeutics Inc (TRDA) as of Dec 05 2025?